Response to willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial [5]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 3, 2003, Pages 412-

  Halpern, Scott D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL; DRUG USE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; LETTER; PREDICTION; PRIORITY JOURNAL; SELF REPORT;

EID: 0037488356     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200307010-00020     Document Type: Letter

References (4)

1. O'Connell JM, Hogg RS, Chan K, et al. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr. 2002;31:521-528.
2. Halpern SD, Metzger DS, Berlin JA, et al. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr. 2001;27:281-288.
3. Halpern SD. Prospective preference assessment: a method to enhance the ethics and efficiency of randomized controlled trials. Control Clin Trials. 2002;23:274-288.
4. Bartholow BN, MacQueen KM, Douglas JM Jr, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:108-115.